← Search & browse all drugs
VARIOUS › DIAGNOSTIC RADIOPHARMACEUTICALS › TUMOUR DETECTION › Technetium (99mTc) compounds
technetium (99mTc) tilmanocept
V09IA09
Forms & Strengths
- Lyophilized kit containing 1 mg tilmanocept for reconstitution with technetium‑99m per USP
Adult Dosing
- 0.5–1.0 mCi (18.5–37 MBq) intradermal or subareolar injection per lymphatic basin; volume ≤0.2 mL
- Breast cancer: 0.5 mCi per injection site; melanoma: up to 1.0 mCi per site
Pediatric Dosing
- 0.05 mCi/kg (≈0.5–0.75 mCi) intradermal injection, not exceeding 0.5 mCi total
- Children ≤18 kg: 0.25–0.5 mCi (9–18.5 MBq)
Indications
- Sentinel lymph node detection in breast cancer
- Sentinel lymph node mapping in cutaneous melanoma
- Off‑label sentinel node identification in head and neck squamous cell carcinoma
Mechanism of Action
- Binds CD206 mannose receptors on macrophages and dendritic cells within sentinel lymph nodes
- Technetium‑99m radiolabel provides gamma emission for planar and SPECT imaging
- Rapid accumulation in SLN with minimal downstream node uptake
Contraindications
- Known hypersensitivity to tilmanocept or kit excipients
- Pregnancy unless benefit justifies potential fetal radiation exposure
- Breastfeeding – discontinue nursing for 24 h after administration
Adverse Reactions
- Injection site pain or erythema
- Transient nausea
- Urticaria or rash
- Rare anaphylaxis
- Mild headache
Drug Interactions
- No clinically significant drug interactions reported
- Agents altering lymphatic flow may affect SLN uptake
- Competing mannose-containing compounds (e.g., mannan) may reduce binding
- Other radiopharmaceuticals should be administered separately to avoid detector cross‑talk
Curated Content: Needs Vetting Before Put to Clinical Use